Green leaf pharmaceutical high-dose Liss' permeable skin patch has been approved for sale in Germany
Last Update: 2021-02-24
Search more information of high quality chemicals, good prices and reliable suppliers, visit
Pharmaceutical Group announced that the German Federal Institute for Drugs and Medical Devices has approved a single-day skin-through patch for 13.3mg/24h. This dose is a supplement to the existing dosage specifications of 4.6 mg/24h and 9.5 mg/24h, which allows the doctor to provide a more suitable individualized dose depending on the patient's condition.
's single-day permeable patch for the treatment of Alzheimer's disease is one of the core products of Leafy Pharmaceuticals in the central nervous field. Greenlee Pharmaceuticals hopes to continue to strengthen its extensive product line in the field of central neurotherapy, further enhancing the company's core competitiveness and global operations in this area.
At present, Liss's single-day permeable patch has been sold in more than 20 countries around the world, the market performance is good. In the European market, high-dose products will complement the original dose of 4.6 mg/24h and 9.5mg/24h of Liss' single-day permeable patch product line, while in the United States market, all three doses are available. In addition, high-dose products are planned to be available in more markets around the world.
Green leaf pharmaceutical's Liss's single-day permeable patch was developed by its German subsidiary, Luye Pharma AG, on the research and development platform for permeable drugs. It is absorbed by the body by penetrating the skin, avoiding gastrointestinal discomfort caused by oral medications and difficulty swallowing in some patients. Compared with traditional tablets, it can effectively reduce the frequency of administration, reduce fluctuations in blood concentration, and provide controlled drug release. In addition to the one-day patch, Luye Pharma AG is also developing lis's mindfulness permeable patch (LY34010), which is innovative in the way it is given and is a patented and innovative agent, and has now completed key trials in Germany for the treatment of Alzheimer's disease. (U.S. News Agency)
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to firstname.lastname@example.org
. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.